Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option

Retrieved on: 2025-03-13 17:35:32

Tags for this article:

Prevention of HIV/AIDS

Gilead Sciences

Pre-exposure prophylaxis for HIV prevention

Management of HIV/AIDS

HIV/AIDS

Tenofovir disoproxil

HIV

HIV Prevention Trials Network

Click the tags to see associated articles and topics

Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option. View article details on hiswai:

Excerpt

AI & Tech Use in Drug Discovery. February 21st 2024. References. 1. First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV ...

Article found on: www.appliedclinicaltrialsonline.com

View Original Article